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Postmarketing surveillance is useful to collect safety data in real‐world clinical set-
tings. In this study, we applied postmarketing real‐world data on a mechanistic
model analysis for neutropenic profiles of eribulin in patients with recurrent or
metastatic breast cancer. Demographic and safety data were collected using an
active surveillance method from eribulin‐treated recurrent or metastatic breast can-
cer patients. Changes in neutrophil counts over time were analyzed using a mecha-
nistic pharmacodynamic model. Pathophysiological factors that might affect the
severity of neutropenia were investigated, and neutropenic patterns were simulated
for different treatment schedules. Clinical and laboratory data were collected from
401 patients (5199 neutrophil count measurements) who had not received granulo-
cyte colony‐stimulating factor and were eligible for pharmacodynamic analysis. The
estimated mean parameters were as follows: mean transit time = 104.5 h, neutrophil
proliferation rate constant = 0.0377 h−1, neutrophil elimination rate constant
= 0.0295 h−1, and linear coefficient of drug effect = 0.0413 mL/ng. Low serum albu-
min levels and low baseline neutrophil counts were associated with severe neu-
tropenia. The probability of grade ≥3 neutropenia was predicted to be 69%, 27%,
and 27% for patients on standard, biweekly, and triweekly treatment scenarios,
respectively, based on virtual simulations using the developed pharmacodynamic
model. In conclusion, this is the first application of postmarketing surveillance data
to a model‐based safety analysis. This analysis of safety data reflecting authentic
clinical settings will provide useful information on the safe use and potential risk
factors of eribulin.
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1 | INTRODUCTION
Breast cancer is the most common cancer in women; in 2012, there
were an estimated 1.67 million new cases and 0.52 million deaths
from breast cancer worldwide.1 Cytotoxic chemotherapies based on
anthracyclines and taxanes are the primary therapeutic options for
recurrent or metastatic breast cancer (RBC/MBC). However, the dis-
ease often progresses due to primary or acquired resistance to these
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treatment regimens, and there are few subsequent therapeutic
options for patients with refractory disease.2 Over the past several
years, eribulin mesilate, a microtubule inhibitor, has shown reason-
able efficacy with acceptable toxicity in patients with RBC/MBC.3-5
The phase III EMBRACE trial of eribulin mesilate for women with
pretreated metastatic breast cancer showed promising results, show-
ing a significant improvement in median overall survival of
2.5 months compared with the treatment of physician's choice.3
Eribulin mesilate was approved for the treatment of RBC/MBC in
Japan in April 2011 based on a phase II domestic trial of 81 patients
and premarketing clinical studies of only a small number of Japanese
patients.6 Grade ≥3 neutropenia occurring during eribulin treatment
appears to be more frequent in studies of East Asian populations
(85%‐95%) than of global populations (20%‐65%).7,8 Therefore, it is
important that more information is obtained on the safety and toxic-
ity of eribulin treatment, especially in Japanese patients.
Japanese regulations require postmarketing surveillance studies
of new chemical entities and biological products to confirm their
safety. A considerable amount of data has been reported by physi-
cians who prescribe eribulin mesilate; however, the data generally
only document and confirm the frequency of toxicities.9 Here, we
used observational safety data to carry out a model‐based pharma-
codynamic analysis of the safety profile of eribulin in the clinical set-
ting of patients with RBC/MBC. The major reported adverse events
and dose‐limiting toxicities associated with eribulin treatment include
neuropathy and neutropenia.10 As severe neutropenia often requires
changes in treatment schedules in the clinical setting, we focused on
analysis of neutropenia as the most common toxicity related to
eribulin treatment.
2 | MATERIALS AND METHODS
2.1 | Patients
Between July 2011 and December 2011, demographic and safety
data were collected by the surveillance method from eribulin‐naïve
RBC/MBC patients who were treated with eribulin mesilate in 325
centers in Japan. Patients with contraindications to treatment (high
myelosuppression, known hypersensitivity to eribulin mesilate, preg-
nancy, or the possibility of pregnancy) were excluded from the post-
marketing surveillance. The postmarketing surveillance of eribulin
was carried out in accordance with Japanese regulatory require-
ments called Good Post‐Marketing Study Practice. In addition, all
personal information related to the surveillance was managed to be
anonymous in accordance with privacy protection laws. The Ethics
Committee of Keio University School of Medicine (Tokyo, Japan)
approved the retrospective pharmacodynamic analysis using anony-
mous data collected by the postmarketing surveillance of eribulin.
2.2 | Postmarketing surveillance data
Postmarketing surveillance data for eribulin treatment included gen-
der, age, ECOG performance status (PS), history of treatment with
cytotoxic agents, complete blood counts (including absolute neu-
trophil counts at baseline [BNEU]), serum chemistries (serum albumin
[ALB], total bilirubin [BILI], and alkaline phosphatase [ALP]), injection
date, and dose of eribulin mesilate. Collection of all laboratory
parameters, including neutrophil counts, was arbitrary with respect
to time and frequency because examination and treatment schedules
varied with the patient's clinical situation. The observation period for
neutrophil counts and the timing of eribulin dose reduction were
also different for each patient.
2.3 | Establishment of a population
pharmacokinetic/pharmacodynamic model for eribulin
The population pharmacokinetic (PK)/pharmacodynamic (PD) model
for eribulin is shown in Figure 1. Plasma eribulin concentrations were
simulated based on a population PK model developed by Majid et
al,11 who reported that eribulin PK could be described by a three‐
compartment model with linear elimination from the central com-
partment and overall steady‐state exposure (area under the curve)
that increased proportionally with the total eribulin dose. The follow-
ing PK parameters were calculated from the Majid et al population
PK model using individual patient demographic data to simulate the
PK profile: clearance (CL [L/h]), volume of compartments (V1, V2 and
V3 [L]), and intercompartmental clearance (Q2 and Q3 [L/h]). CL, Q2,
and Q3 were normalized by body weight (WGT). CL was dependent
on the values of ALB, ALP, and BILI.
CL½L=h ¼ 3:11ðWGT
68:7
Þ0:75ðALB
4:0
Þ0:946ðALP
132
Þð0:209Þ  ðBILI
0:5
Þð0:180Þ
V1 ½L ¼ 4:06WGT
68:7
Q2 ½L=h ¼ 2:64ðWGT
68:7
Þ0:75
V2 ½L ¼ 2:42WGT
68:7
Q3 ½L=h ¼ 6:60ðWGT
68:7
Þ0:75
V3 ½L ¼ 121WGT
68:7
The given dose of eribulin was converted to the free base equiv-
alent, which was used in the calculations. An eribulin mesilate i.v.
infusion dose of 1.4 mg/m2 was equivalent to an eribulin‐free base
dose of 1.23 mg/m2.
A mechanistic PD model for neutropenia during eribulin treat-
ment reported by Friberg et al12 was used to describe neutrophil
count vs time profiles with simulated plasma concentrations (C) of
eribulin in individual patients. The model consisted of four system‐
dependent and drug‐dependent parts (Figure 1): (i) proliferation of
the progenitor cell compartment; (ii) maturation, represented in the
model by three transit compartments (Tr1, Tr2, and Tr3); (iii) elimina-
tion of circulating neutrophils; and (iv) homeostatic feedback regula-
tion. Steps (i) – (iv) can be described by the following PD
parameters: mean transit time through the neutrophil maturation
delay chain (MTT [h]), neutrophil proliferation rate constant (Kprol [
h−1]), neutrophil elimination rate constant (Kout [h−1]), feedback
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constant (Gamma), and linear coefficient of drug effect (Slope [mL/
ng]). Edrug means drug effect, and Ktr is the transit rate (Tr) con-
stant from one compartment to the next. MTT was converted as 4/
Ktr in the following formulae.
dProl
dt
¼ Kprol Prol ð1 EdrugÞ  ðBNEU
Neu
ÞGamma  Ktr Prol
dTr1
dt
¼ Ktr Prol Ktr Tr1
dTr2
dt
¼ Ktr Tr1 Ktr Tr2
dTr3
dt
¼ Ktr Tr2 Ktr Tr3
dNeu
dt
¼ Ktr Tr3 KoutNeu
Edrug ¼ Slope C
Computation was carried out using Phoenix NLME software
version 7.0 (Certara, Princeton, NJ, USA) with a first‐order method
on a HP Z640 workstation (Intel Xeon E5 processor, 2.60 GHz,
28 cores).
2.4 | Determination of clinical factors that affect
safety
We undertook the multivariate analysis using a stepwise method to
search for clinical factors that could influence neutropenia. The poten-
tial factors analyzed included age, ECOG PS, laboratory data (BNEU
and ALB), and the number of previous chemotherapy regimens. Final
covariate selection was carried out using the likelihood ratio test based
on differences in the objective function value. P < .05 was considered
significant. Based on the final model, a Monte Carlo simulation was
carried out to estimate the predictability of neutropenia of grade 3
(<1000/μL) and grade 4 (<500/μL) according to the Common Terminol-
ogy Criteria for Adverse Events (version 4.0). The simulations were
conducted according to three treatment scenarios: (i) i.v. infusion on
day 1 and day 8 every 21 days (standard scenario); (ii) i.v. infusion on
day 1 and day 15 every 28 days (biweekly scenario); and (iii) i.v. infu-
sion on day 1 every 21 days (triweekly scenario).
F IGURE 1 A, Mechanistic pharmacokinetic/pharmacodynamic model to describe neutrophil count profiles. BNEU, absolute neutrophil
count at baseline; CL, clearance; Gamma, feedback constant; Kout, neutrophil elimination rate constant; Kprol, neutrophil proliferation
rate constant; Ktr, neutrophil transition rate constant; MTT, mean transit time; Q, intercompartmental clearance; V, volume of
compartment
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3 | RESULTS
3.1 | Study population and patient characteristics
Patients with RBC/MBC who were receiving eribulin treatment for
the first time and had not received granulocyte colony‐stimulating
factor (G‐CSF) were enrolled in this study. A flowchart showing
selection of the final study population is presented in Figure 2. Of
the 608 patients whose data were collected, a total of 207 were
excluded for the following reasons: 182 patients lacked data for
ALB, and/or ALP, and/or BILI; and 25 patients lacked data for BNEU.
Finally, 401 patients with a total of 5199 neutrophil count measure-
ments were eligible for the PD analysis.
Characteristics of the study population are shown in Table 1.
The median age was 58 years (range, 26‐84 years), and the median
number of previous chemotherapy regimens, including taxanes, was
4 (range, 0‐13). The planned eribulin treatment regimen was i.v.
administration of 1.4 mg/m2 on days 1 and 8 every 3 weeks.
Depending on the individual patient's condition (eg, disorder of liver
function such as elevated aspartate aminotransferase or alanine
F IGURE 2 Overview of the study population of eribulin‐treated recurrent or metastatic breast cancer patients. Of the 608 starting patient
population who had not been treated with granulocyte colony‐stimulating factor, a total of 401 patients were eligible for pharmacodynamic
analysis. ALB, serum albumin level; ALP, alkaline phosphatase level; BILI, total bilirubin level; BNEU, absolute neutrophil count at baseline
TABLE 1 Characteristics of study population of eribulin‐treated recurrent or metastatic breast cancer patients
Treatment schedule Total (n = 401) Standard (n = 275) Biweekly (n = 64) Triweekly (n = 50)
Dose (mg/m2)
Median 1.4
Range 0.7‐1.4
Age
Median 58 58 58.5 59
Range 26‐84 26‐81 33‐84 40‐74
ECOG performance status (n)
0‐1 192 138 24 22
2 172 121 27 20
≥3 37 16 13 8
Number of previous CTx regimens (n)
0 11 9 1 1
1 31 17 6 5
2‐4 194 127 33 28
≥5 165 122 24 16
Serum albumin (g/dL)
Median 3.9 3.9 3.7 3.7
Range 1.3‐5.1 1.4‐5 1.7‐4.8 1.4‐4.8
Baseline neutrophil count (/μL)
Median 3200 3432 3204 2972
Range 943‐15 000 943‐15 002 1090‐9430 1040‐6712
CTx, chemotherapy.
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aminotransferase), the eribulin dose was reduced to 0.7 mg/m2, the
treatment schedule was modified, doses were skipped, or treatment
was discontinued based on the physicians’ decision.
3.2 | Pharmacokinetic/pharmacodynamic model and
clinical factors affecting toxicity
We developed a population PK/PD model describing eribulin‐induced
neutropenia using the postmarketing surveillance data collected from
401 patients. The following parameters were estimated: MTT (h),
Kprol (h−1), Kout (h−1), Gamma, and Slope (mL/ng). Clinical factors
that could influence the severity of neutropenia were searched using
a shotgun algorithm. We found that age (<65 or ≥65 years), ECOG
PS (<2 or ≥2), and the number of previous chemotherapy regimens
(<5 or ≥5) were not related to neutropenia. However, BNEU and
ALB were suggested to influence neutropenic toxicity, in that lower
BNEU was associated with higher Kprol and lower ALB was associ-
ated with higher Kprol, lower MTT, and lower Kout. In contrast,
Slope was not influenced by any factors.
The final PK/PD model incorporating the clinical factors that
influenced neutropenia is shown in Table 2. The key estimated mean
parameters were as follows: MTT = 104.5 h, Kprol = 0.0377 h−1,
Kout = 0.0295 h−1, Gamma = 0.203, and Slope = 0.0413 mL/ng. We
confirmed the validity and robustness of the obtained PD parame-
ters by a bootstrap method. A total of 182 of the 200 bootstrap
runs reached successful convergence, and the bootstrap mean/final
estimate ratio was within a reasonable range (97.5%‐142.8%). Final
estimates of the model parameters were similar to those previously
reported using premarketing clinical trial data.13
3.3 | Model‐based simulation according to the
treatment scenario
We next investigated the absolute neutrophil counts during the
21 days of cycle 1 of eribulin treatment (Figure 3). Neutropenic toxi-
city was influenced by both ALB levels (Figure 3A) and BNEU (Fig-
ure 3B), although the impact varied with the treatment schedule. In
patients with low albumin levels, the toxicity, in terms of nadir
counts and delayed recovery, was most severe in group 1 (standard
treatment scenario, n = 275) compared with group 2 (biweekly sce-
nario, n = 64) and group 3 (triweekly scenario, n = 50). Twelve
patients with other treatment scenarios were excluded from this
analysis.
3.4 | Risk prediction based on the PD simulation
Based on the simulated absolute neutrophil counts in cycle 1
obtained with the PK/PD model, we ran simulated analyses of
401 patients in the standard, biweekly, and triweekly treatment
scenarios to predict the severity of neutropenia. From this, the
probability of grade ≥3 and ≥4 neutropenia was estimated to be
69% and 23% on the standard scenario, 27% and 3% on the
biweekly scenario, and 27% and 3% on the triweekly scenario,
respectively (Figure 4).
TABLE 2 Final parameter estimates and bootstrap validation of the population pharmacodynamic model for eribulin
Parametersa
Final estimates of
the model parameters
Results of 182 bootstrap simulations
Bootstrap mean/
final estimate ratio (%)Mean 95% CI
tvKprol (h−1) 0.0377 0.0388 0.0303 to 0.0472 102.9
tvMTT (h) 104.5 103.1 82.1 to 124.1 98.7
tvKout (h−1) 0.0295 0.0315 0.0142 to 0.0489 106.8
tvGamma 0.203 0.198 0.157 to 0.239 97.5
tvSlope (mL/ng) 0.0413 0.0408 0.0320 to 0.0496 98.8
θALBKprol −0.759 −0.768 −1.110 to −0.427 101.2
θALBMTT 0.605 0.626 0.278 to 0.973 103.5
θALBKout 0.357 0.403 −0.144 to 0.950 112.9
θBNEUKprol 0.0704 0.0693 0.0432 to 0.0953 98.4
ω2Kprol 0.00417 0.00409 0.00212 to 0.00606 98.1
ω2Kout 0.374 0.534 −0.270 to 1.340 142.8
ω2slope 0.163 0.168 0.106 to 0.229 103.1
σ (/nL) 1.15 1.13 1.03 to 1.23 98.3
ω2Kout, ω
2
Kprol, ω
2
slope, variances of interindividual variability; σ, standard deviation of residual variability; θALBMTT, effect of ALB on MTT; θALBKout,
effect of ALB on Kout; θALBKprol, effect of ALB on Kprol; θBNEUKprol, effect of BNEU on Kprol; ALB, albumin; BNEU, absolute neutrophil count at
baseline; CI, confidence interval; Gamma, feedback constant; Kout, neutrophil elimination rate constant; Kprol, neutrophil proliferation rate constant;
MTT, mean transit time; Slope, linear coefficient of drug effect; tv, typical value.
aPopulation PD model parameter estimates for eribulin:
MTT ¼ tvMTT ðALB4 ÞθALBMTT; Kprol ¼ tvKprol ðALB4 ÞθALBKprol  ð1þ BNEU3 θBNEU3KprolÞ
If baseline neutrophil counts <3000, then BNEU3 = 1; if ≥3000, then BNEU3 = 0.
Kout ¼ tvKout ðALB4 ÞθALBKout
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4 | DISCUSSION
This is the first large‐scale PD study of eribulin therapy in RBC/MBC
patients using postmarketing surveillance safety data. Population PK/
PD analyses of eribulin‐associated neutropenia published to date
have been based on data obtained in premarketing clinical trials that
had strict eligibility criteria and treatment schedules.13 However, our
study here shows that postmarketing surveillance data can also be
used for a model‐based safety analysis. The use of postmarketing
data to investigate drug safety profiles is advantageous because it is
derived from patients with broader backgrounds in more realistic
clinical settings. Furthermore, the variability in treatment schedules
based on each patient's physical condition provides additional infor-
mation about treatment schedules that differ from the standard regi-
men.
Data on plasma concentrations of drug were not available in this
postmarketing surveillance; therefore, plasma eribulin concentrations
were simulated using the population PK model reported by Majid et
al. In their analysis, efficacy and safety data from seven phase I stud-
ies, one phase II study, and one phase III study were combined to
characterize the PK and exposure‐efficacy relationship of eribulin.
The results of that study suggested that their PK model was also
applicable for analyzing the safety of eribulin treatment, especially
dose‐limiting toxicities.
In the present study, the PD simulations revealed that low ALB
and low BNEU were both associated with severe neutropenia. A PK/
PD model of docetaxel, for which neutropenia is also a dose‐limiting
toxicity, showed that ALB influenced the CL and EC50 of docetaxel;
indeed, both factors had a strong impact on the development of
neutropenia.14 Although it seems reasonable that a lower BNEU
would lead to more severe neutropenia after eribulin treatment, the
mechanism by which ALB influences the nadir neutrophil count
remains unclear. Malnutrition‐related low ALB levels have been sug-
gested to influence drug PD.15,16 Binding of eribulin to human
plasma proteins ranges from 49% to 65% at concentrations from
100 to 1000 ng/mL.17 Therefore, it is unlikely that the severity of
F IGURE 3 Effects of serum albumin level and baseline neutrophil counts on neutropenia in eribulin‐treated recurrent or metastatic breast
cancer patients (n = 401). A, Effect of albumin levels. Black, dashed, and dotted lines indicate normal (3.9 g/dL), low (3.0 g/dL), and severely
reduced (1.5 g/dL) serum albumin levels, respectively. Earlier and deeper nadirs were observed in patients with low albumin levels in each
group. B, Effect of baseline neutrophil counts. Black and dotted lines indicate normal (3200/μL) and severely reduced (1500/μL) neutrophil
counts, respectively. The difference between normal and severely reduced absolute neutrophil counts was greater in group 3 than in groups 1
or 2. For A and B, group 1, standard treatment scenario (n = 275), i.v. infusion on day 1 and day 8 every 21 days; group 2, biweekly scenario
(n = 64), i.v. infusion on day 1 and day 15 every 28 days; group 3, triweekly scenario (n = 50), i.v. infusion on day 1 every 21 days
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neutropenic toxicity is caused by elevation of plasma‐free eribulin
concentrations resulting from low ALB levels. Further studies will be
needed to clarify the mechanism.
Our simulation showed that the beginning, duration, and depth
of the nadir in on‐treatment neutrophil counts varied with the eribu-
lin treatment schedules. These predictions cannot be led from simple
summarization of the observed data because actual intervention can
carry a selection bias; only patients with particular characteristics
were allocated to the alternative schedule. Modeling and simulation
can be a useful tool for investigating and evaluating an optimal treat-
ment strategy in a variety of virtual treatment options.
Physicians were permitted any treatment modification based on
the patient's clinical situation, and the surveillance data indicated
that treatment schedules were modified to avoid severe toxicity. Of
note, the surveillance data revealed that approximately 30% of
patients required a reduction in dosing frequency due to neutropenic
toxicity during the first cycle of eribulin treatment. Several prospec-
tive studies exploring alternative treatment schedules of eribulin
have been carried out worldwide.18,19 The multicenter phase II study
undertaken in Japan (JUST‐STUDY) investigated a new dosing regi-
men aimed at controlling eribulin toxicity, mainly febrile neutropenia.
The study found that biweekly eribulin administration showed com-
parable efficacy and helped to control eribulin toxicity for women
with previously treated MBC who were unable to continue on the
standard schedule of eribulin.18 In the present study, our simulation
also suggests that the probability of severe neutropenia (grade ≥3)
would be reduced from 69% on the standard scenario to 27% on
the biweekly scenario. Although the triweekly scenario was also
shown to be less toxic, its efficacy might be compromised by the
lower total dose. Further phase III studies of biweekly eribulin are
needed to verify comparable efficacy and improved safety.
This study is the first large‐scale PD analysis of eribulin toxicity,
although it is limited by its retrospective nature. Various patient
factors and comorbidities could influence the eribulin toxicity profiles,
because data collected by postmarketing surveillance are more hetero-
geneous than data from prospectively controlled studies. Therefore,
our results are expected to reflect a real‐world setting in which follow‐
up intervals and dosing schedules are tailored to each patient. How-
ever, in the present study, 35% of the total patients were excluded
from the original surveillance data to avoid the influence of G‐CSF.
This means that the recovery process from neutropenia by treatment
with G‐CSF was not analyzed in the present study.
In conclusion, neutrophil count data collected by a postmarketing
surveillance method were successfully applied to a model‐based
safety analysis for eribulin in patients with RBC/MBC. Our study
showed that ALB levels and BNEU affected the severity of neu-
tropenia. Using our PK/PD model, we simulated the severity of neu-
tropenic toxicity under different treatment scenarios and found that
a biweekly scenario could lower the probability of severe neutrope-
nia. This analysis of real‐world safety data reflecting authentic clinical
settings will provide useful information on the safety and potential
risk factors of eribulin.
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